Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Pot ingredient for epilepsy.

Sneed A.

Sci Am. 2014 May;310(5):29. No abstract available.

PMID:
24783586
2.

Cannabidiol and medical marijuana for the treatment of epilepsy.

Mathern G, Nehlig A, Sperling M.

Epilepsia. 2014 Jun;55(6):781-2. doi: 10.1111/epi.12647. No abstract available.

3.

Commentary: medical marijuana survey & epilepsy.

Devinsky O.

Epilepsia. 2015 Jan;56(1):7-8. doi: 10.1111/epi.12853. No abstract available.

4.

Potential therapeutical effects of cannabidiol in children with pharmacoresistant epilepsy.

Cortesi M, Fusar-Poli P.

Med Hypotheses. 2007;68(4):920-1. No abstract available.

PMID:
17112679
5.

Chronic administration of cannabidiol to healthy volunteers and epileptic patients.

Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sanvito WL, Lander N, Mechoulam R.

Pharmacology. 1980;21(3):175-85.

PMID:
7413719
6.

Toward drugs derived from cannabis.

Mechoulam R, Carlini EA.

Naturwissenschaften. 1978 Apr;65(4):174-9. Review.

PMID:
351429
7.

Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis.

Borrelli F, Aviello G, Romano B, Orlando P, Capasso R, Maiello F, Guadagno F, Petrosino S, Capasso F, Di Marzo V, Izzo AA.

J Mol Med (Berl). 2009 Nov;87(11):1111-21. doi: 10.1007/s00109-009-0512-x.

PMID:
19690824
8.

Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer.

Aviello G, Romano B, Borrelli F, Capasso R, Gallo L, Piscitelli F, Di Marzo V, Izzo AA.

J Mol Med (Berl). 2012 Aug;90(8):925-34. doi: 10.1007/s00109-011-0856-x.

PMID:
22231745
9.

Cannabidiol in dystonic movement disorders.

Sandyk R, Snider SR, Consroe P, Elias SM.

Psychiatry Res. 1986 Jul;18(3):291. No abstract available.

PMID:
3749389
10.

Cannabidiol: a prion therapy for mice?

Dicou E.

J Neurosci Res. 2008 May 1;86(6):1417-8. doi: 10.1002/jnr.21694. No abstract available.

PMID:
18338806
11.

Antipsychotic effect of cannabidiol.

Zuardi AW, Morais SL, GuimarĂ£es FS, Mechoulam R.

J Clin Psychiatry. 1995 Oct;56(10):485-6. No abstract available.

PMID:
7559378
12.

Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.

Schier AR, Ribeiro NP, Silva AC, Hallak JE, Crippa JA, Nardi AE, Zuardi AW.

Rev Bras Psiquiatr. 2012 Jun;34 Suppl 1:S104-10. Review. English, Portuguese.

13.

Cannabidiol--recent advances.

Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO.

Chem Biodivers. 2007 Aug;4(8):1678-92. Review.

PMID:
17712814
14.

Interactions between cannabidiol and delta9-THC during abstinence in morphine-dependent rats.

Hine B, Torrelio M, Gershon S.

Life Sci. 1975 Sep 15;17(6):851-7. No abstract available.

PMID:
1238886
15.

Cannabidiol treatment ameliorates ischemia/reperfusion renal injury in rats.

Fouad AA, Al-Mulhim AS, Jresat I.

Life Sci. 2012 Sep 17;91(7-8):284-92. doi: 10.1016/j.lfs.2012.07.030.

PMID:
22877651
16.

Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats.

Fouad AA, Jresat I.

Eur J Pharmacol. 2011 Nov 16;670(1):216-23. doi: 10.1016/j.ejphar.2011.08.048.

PMID:
21930120
17.

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.

Zuardi AW.

Rev Bras Psiquiatr. 2008 Sep;30(3):271-80. Review.

18.

Cannabidiol as potential anticancer drug.

Massi P, Solinas M, Cinquina V, Parolaro D.

Br J Clin Pharmacol. 2013 Feb;75(2):303-12. doi: 10.1111/j.1365-2125.2012.04298.x. Review.

19.

Therapeutic time window of cannabidiol treatment on delayed ischemic damage via high-mobility group box1-inhibiting mechanism.

Hayakawa K, Irie K, Sano K, Watanabe T, Higuchi S, Enoki M, Nakano T, Harada K, Ishikane S, Ikeda T, Fujioka M, Orito K, Iwasaki K, Mishima K, Fujiwara M.

Biol Pharm Bull. 2009 Sep;32(9):1538-44.

20.

Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia.

Gururajan A, Taylor DA, Malone DT.

Behav Brain Res. 2011 Sep 23;222(2):299-308. doi: 10.1016/j.bbr.2011.03.053.

PMID:
21458498
Items per page

Supplemental Content

Support Center